Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications
- PMID: 10446995
Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications
Abstract
Elevated tumor interstitial fluid pressure (IFP) is partly responsible for the poor penetration and distribution of therapeutic agents in solid tumors. The etiology of tumor interstitial hypertension is poorly understood. We have postulated that the solid stress generated by tumor cells growing in a confined space compresses blood vessels and increases tumor microvascular pressure and IFP. To test the hypothesis that neoplastic cell loss would decompress blood vessels and lower IFP, we induced apoptosis in tumors with paclitaxel and docetaxel. Taxanes inhibited the growth of the murine mammary carcinoma (MCa-IV) and of the human soft tissue sarcoma (HSTS-26T). Taxanes induced apoptosis and reduced the density of intact neoplastic cells in both MCa-IV and HSTS-26T. To determine whether neoplastic cell loss decompressed blood vessels, we measured the diameter of tumor vessels in HSTS-26T tumors implanted in transparent dorsal skin fold chambers. At 48 and 96 h after paclitaxel, the diameter of tumor vessels was significantly increased. The increase in vascular diameters was associated with reductions in microvascular pressure and IFP. The changes in neoplastic cell density and IFP were also correlated. In the human glioblastoma U87, which is resistant to paclitaxel, the IFP and cellular density were not modified by paclitaxel treatment. Collectively, these results support the hypothesis that solid stress generated by neoplastic cell proliferation increases vascular resistance and IFP. The increase in vessel diameter induced by paclitaxel and docetaxel suggests that taxanes could improve tumor response by increasing the vascular surface area for delivery of therapeutic agents.
Similar articles
-
Lack of correlation between mitotic arrest or apoptosis and antitumor effect of docetaxel.Cancer Chemother Pharmacol. 1999;43(2):165-72. doi: 10.1007/s002800050879. Cancer Chemother Pharmacol. 1999. PMID: 9923824
-
Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.Clin Cancer Res. 1999 Dec;5(12):4191-8. Clin Cancer Res. 1999. PMID: 10632360
-
Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.Clin Cancer Res. 1999 Apr;5(4):891-7. Clin Cancer Res. 1999. PMID: 10213226
-
Combination of taxanes with radiation: preclinical studies.Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):12-26. Semin Radiat Oncol. 1999. PMID: 10210536 Review.
-
Pharmacology of the taxanes.Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):96S-104S. Pharmacotherapy. 1997. PMID: 9322876 Review.
Cited by
-
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.J Clin Oncol. 2013 Jun 10;31(17):2205-18. doi: 10.1200/JCO.2012.46.3653. Epub 2013 May 13. J Clin Oncol. 2013. PMID: 23669226 Free PMC article. Review.
-
Stress-mediated progression of solid tumors: effect of mechanical stress on tissue oxygenation, cancer cell proliferation, and drug delivery.Biomech Model Mechanobiol. 2015 Nov;14(6):1391-402. doi: 10.1007/s10237-015-0682-0. Epub 2015 May 13. Biomech Model Mechanobiol. 2015. PMID: 25968141 Free PMC article.
-
Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.Invest New Drugs. 2006 Jan;24(1):79-83. doi: 10.1007/s10637-005-4542-0. Invest New Drugs. 2006. PMID: 16379039 Clinical Trial.
-
Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.J Cancer Res Clin Oncol. 2019 Dec;145(12):3021-3036. doi: 10.1007/s00432-019-03044-5. Epub 2019 Oct 15. J Cancer Res Clin Oncol. 2019. PMID: 31617075 Review.
-
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.Invest New Drugs. 2001 May;19(2):179-96. doi: 10.1023/a:1010691218625. Invest New Drugs. 2001. PMID: 11392452 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources